Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286627 | 1.00 | CYP3A4 (0.57) | CYP3A4TDP1 | |
| SCHEMBL9943656 | 0.85 | CYP3A4 (0.67) | CYP3A4 | |
| SCHEMBL2954848 | 0.85 | CYP3A4 (0.62) | CYP3A4 | |
| SCHEMBL893198 | 0.85 | CYP3A4 (0.55) | CYP3A4TDP1 | |
| SCHEMBL893460 | 0.85 | CYP3A4 (0.62) | CYP3A4 | |
| SCHEMBL893383 | 0.85 | CYP3A4 (0.55) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL7389969 | 0.84 | CYP3A4 (0.55) | CYP3A4TDP1 | |
| SCHEMBL16281945 | 0.84 | CYP3A4 (0.59) | CYP3A4 | |
| SCHEMBL4246832 | 0.84 | CYP3A4 (0.56) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL31236647 | 0.84 | CYP3A4 (0.55) | CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116687923-A | Application of ritonavir or derivative thereof in preparation of medicines for treating mental disorder | 苏州志恒生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-3578981-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3245514-B1 | MACROMOLECULAR CONJUGATES FOR VISUALIZATION AND SEPARATION OF PROTEINS AND CELLS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-07-10 | — | — | EP | disclosed |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130131085-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2465855-A1 | Cytochrome P450 oxidase inhibitors and uses thereof | Abbott Laboratories (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-20080161246-A1 | Improving the pharmacokinetics of drugs such as antiviral agents that are metabolized by CYP enzymes; N-heterocyclic compounds containing carbamate group, where is excluded; 1,3-thiazol-5-ylmethyl 1,1-dibenzylbut-3-enylcarbamate for example | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1418174-A2 | Amorphous Ritonavir | ABBOTT LABORATORIES (US) | 2004-05-12 | — | — | EP | disclosed |
| US-5580984-A | 1-OXA-3-AZA-2-BORINE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| US-5552558-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CYP3A4 8/4885TDP1 610/4885 |
| US-20080161246-A1 | Improving the pharmacokinetics of drugs such as antiviral agents that are metabolized by CYP enzymes; N-heterocyclic compounds containing carbamate group, where is excluded; 1,3-thiazol-5-ylmethyl 1,1-dibenzylbut-3-enylcarbamate for example | CYP3A4, CYP3A5, CYP2B6 | CYP3A4 1/4885TDP1 463/4885 |
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CYP3A4 8/4885TDP1 610/4885 |
| US-20130131085-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CYP3A4 8/4885TDP1 610/4885 |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CYP3A4 8/4885TDP1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.